Haleon PLC Sponsored ADR $HLN Stake Decreased by GAM Holding AG

GAM Holding AG trimmed its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 8.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 606,673 shares of the company’s stock after selling 59,257 shares during the quarter. GAM Holding AG’s holdings in Haleon were worth $5,442,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in HLN. Brighton Jones LLC acquired a new stake in shares of Haleon during the 4th quarter valued at $187,000. Ieq Capital LLC raised its position in shares of Haleon by 8.0% during the first quarter. Ieq Capital LLC now owns 30,502 shares of the company’s stock worth $314,000 after purchasing an additional 2,251 shares during the period. Baird Financial Group Inc. lifted its holdings in shares of Haleon by 264.6% during the first quarter. Baird Financial Group Inc. now owns 69,350 shares of the company’s stock valued at $714,000 after purchasing an additional 50,328 shares during the last quarter. Royal Bank of Canada increased its stake in Haleon by 1.5% in the 1st quarter. Royal Bank of Canada now owns 2,775,678 shares of the company’s stock worth $28,561,000 after purchasing an additional 42,063 shares in the last quarter. Finally, AQR Capital Management LLC raised its holdings in Haleon by 22.5% during the 1st quarter. AQR Capital Management LLC now owns 96,323 shares of the company’s stock worth $991,000 after buying an additional 17,720 shares during the period. 6.67% of the stock is currently owned by institutional investors.

Haleon Trading Down 0.9%

Shares of NYSE:HLN opened at $10.02 on Friday. The firm has a fifty day moving average of $9.67 and a two-hundred day moving average of $9.65. The company has a quick ratio of 0.63, a current ratio of 0.87 and a debt-to-equity ratio of 0.48. Haleon PLC Sponsored ADR has a 12-month low of $8.71 and a 12-month high of $11.42. The firm has a market capitalization of $44.60 billion, a P/E ratio of 25.68 and a beta of 0.19.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Monday, December 15th. Weiss Ratings reiterated a “hold (c)” rating on shares of Haleon in a research report on Wednesday, October 8th. Barclays lowered Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Finally, The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $12.33.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.